Autolus Therapeutics plc (AUTL)
NASDAQ: AUTL · Real-Time Price · USD
1.440
+0.020 (1.41%)
At close: Jan 15, 2026, 4:00 PM EST
1.440
0.00 (0.00%)
Pre-market: Jan 16, 2026, 6:06 AM EST
Autolus Therapeutics Employees
As of December 31, 2024, Autolus Therapeutics had 650 total employees, including 647 full-time and 3 part-time employees. The number of employees increased by 179 or 38.00% compared to the previous year.
Employees
650
Change (1Y)
179
Growth (1Y)
38.00%
Revenue / Employee
$78,658
Profits / Employee
-$345,849
Market Cap
383.25M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 650 | 179 | 38.00% |
| Dec 31, 2023 | 471 | 67 | 16.58% |
| Dec 31, 2022 | 404 | 77 | 23.55% |
| Dec 31, 2021 | 327 | -57 | -14.84% |
| Dec 31, 2020 | 384 | 92 | 31.51% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
AUTL News
- 4 days ago - Autolus Therapeutics Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Net Product Revenue, Pipeline Advancements and Outlook for 2026 - GlobeNewsWire
- 9 days ago - Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell ShuttleTM Platform - Business Wire
- 9 days ago - Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell Shuttle™ Platform - GlobeNewsWire
- 5 weeks ago - Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025 - GlobeNewsWire
- 5 weeks ago - Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025 - GlobeNewsWire
- 6 weeks ago - Autolus Therapeutics Appoints Ryan Richardson to Board of Directors - GlobeNewsWire
- 7 weeks ago - Why Is Autolus Therapeutics Stock Trading Higher On Tuesday? - Benzinga
- 7 weeks ago - NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹ - GlobeNewsWire